Management of Angiotensin Receptor Blockers with Elevated Creatinine

Introduction to ARB Therapy

The American College of Cardiology recommends not discontinuing ARB therapy for creatinine increases up to 30% above baseline in stable, euvolemic patients, as this hemodynamic effect reflects the intended mechanism of renoprotection and predicts better long-term kidney outcomes 1, 2, 3

The European Society of Cardiology states that ARBs block angiotensin II-mediated efferent arteriolar constriction, reducing intraglomerular pressure and filtration rate, which manifests as increased serum creatinine 2
The American Heart Association notes that this mechanism is independent of blood pressure changes and represents altered renal hemodynamics rather than tubular damage 2
The National Kidney Foundation indicates that creatinine increases up to 30% from baseline are expected and do not represent actual kidney injury—true acute tubular necrosis would show positive biomarkers like NGAL and KIM-1, whereas hemodynamic creatinine rises do not 2

The American College of Cardiology recommends continuing ARB at current dose if creatinine increase is <30% above baseline, and verifying adequate hydration status and excluding volume depletion 3, 4
The European Society of Cardiology suggests stopping potassium supplements and potassium-sparing diuretics if creatinine increase is 30-50% above baseline, and considering reducing loop or thiazide diuretic dose if no clinical congestion present 3, 4
The American Heart Association recommends halving the ARB dose immediately if creatinine increase is >50% or absolute value >266 μmol/L (3 mg/dL), and assessing for reversible causes: volume depletion, NSAIDs, contrast exposure, bilateral renal artery stenosis 3, 5

The National Kidney Foundation advises temporarily holding ARBs during intercurrent illness with volume depletion, IV radiocontrast administration, bowel preparation procedures, major surgery, or active acute kidney injury with volume depletion 1, 2, 4

The American College of Cardiology recommends checking creatinine and potassium within 1 week after ARB initiation or dose increase, and monitoring at least annually for eGFR ≥60 mL/min/1.73 m², and more frequently (every 3-6 months) for eGFR <60 mL/min/1.73 m² 1, 3, 4

The American Heart Association notes that risk factors for hyperkalemia with ARBs include baseline renal insufficiency, heart failure, and concomitant use of potassium-sparing diuretics, potassium supplements, or NSAIDs 6, 1
The European Society of Cardiology recommends using potassium-wasting diuretics, discontinuing potassium supplements and potassium-based salt substitutes, avoiding NSAIDs, and considering potassium-binding agents if needed to maintain ARB therapy 6, 1

The European Society of Cardiology recommends cautious use of ARBs in advanced CKD (eGFR <30 mL/min/1.73 m²), with close monitoring of renal function and potassium, and referral to nephrology for management 6, 4
The American College of Cardiology suggests starting losartan at 25 mg daily in mild-moderate hepatic impairment, and monitoring plasma concentrations 2
The American Geriatrics Society notes that age ≥65 years is associated with lower GFR for given creatinine levels, and recommends monitoring for volume depletion, which is more common in elderly 5, 1